Company Description
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder.
The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment.
The company has a collaboration with Merck & Co., Inc. to develop α7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer’s disease and other central nervous system conditions.
The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024.
Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Spyridon Papapetropoulos |
Contact Details
Address: 100 Summit Dr Burlington, Massachusetts 01803 United States | |
| Phone | 781-730-6665 |
| Website | neuphoriatx.com |
Stock Details
| Ticker Symbol | NEUP |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001191070 |
| ISIN Number | US64136E1029 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Spyridon Papapetropoulos M.D., Ph.D. | Chief Executive Officer, President and Director |
| Timothy M. Cunningham CPA, M.B.A. | Chief Financial Officer |
| Elizabeth Doolin | Senior Vice President of Clinical Development |
| Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer |
| Adrian Hinton BEC, F.C.A. | Financial Controller |
| Rajeev Chandra B.Com., C.A., M.B.A. | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | 10-Q | Quarterly Report |
| Feb 12, 2025 | 424B5 | Filing |
| Feb 4, 2025 | 424B5 | Filing |
| Jan 29, 2025 | EFFECT | Notice of Effectiveness |
| Jan 28, 2025 | SCHEDULE 13D/A | Filing |
| Jan 28, 2025 | UPLOAD | Filing |
| Jan 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 24, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 14, 2025 | 8-K | Current Report |